Evidence map›Paper›PMID 34079578›Full record

ArticleFrontiers in genetics2021

Breast Cancer Case Identification Based on Deep Learning and Bioinformatics Analysis.

Dongfang Jia, Cheng Chen, Chen Chen, Fangfang Chen, Ningrui Zhang, Ziwei Yan, Xiaoyi Lv

Abstract read
In one paragraph

Article in Frontiers in genetics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Accurate breast cancer diagnosis using a stable feature ranking algorithm.BMC medical informatics and decision making · 2023
    Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Dongfang JiaCollege of Information Science and Engineering, Xinjiang University, Urumqi, China.
Cheng ChenCollege of Information Science and Engineering, Xinjiang University, Urumqi, China.
Chen ChenCollege of Information Science and Engineering, Xinjiang University, Urumqi, China.
Fangfang ChenCollege of Information Science and Engineering, Xinjiang University, Urumqi, China.
Ningrui ZhangCollege of Information Science and Engineering, Xinjiang University, Urumqi, China.
Ziwei YanCollege of Information Science and Engineering, Xinjiang University, Urumqi, China.
Xiaoyi LvCollege of Information Science and Engineering, Xinjiang University, Urumqi, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Mastering the molecular mechanism of breast cancer (BC) can provide an in-depth understanding of BC pathology. This study explored existing technologies for diagnosing BC, such as mammography, ultrasound, magnetic resonance imaging (MRI), computed tomography (CT), and positron emission tomography (PET) and summarized the disadvantages of the existing cancer diagnosis. The purpose of this article is to use gene expression profiles of The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) to classify BC samples and normal samples. The method proposed in this article triumphs over some of the shortcomings of traditional diagnostic methods and can conduct BC diagnosis more rapidly with high sensitivity and have no radiation. This study first selected the genes most relevant to cancer through weighted gene co-expression network analysis (WGCNA) and differential expression analysis (DEA). Then it used the protein-protein interaction (PPI) network to screen 23 hub genes. Finally, it used the support vector machine (SVM), decision tree (DT), Bayesian network (BN), artificial neural network (ANN), convolutional neural network CNN-LeNet and CNN-AlexNet to process the expression levels of 23 hub genes. For gene expression profiles, the ANN model has the best performance in the classification of cancer samples. The ten-time average accuracy is 97.36% (±0.34%), the F1 value is 0.8535 (±0.0260), the sensitivity is 98.32% (±0.32%), the specificity is 89.59% (±3.53%) and the AUC is 0.99. In summary, this method effectively classifies cancer samples and normal samples and provides reasonable new ideas for the early diagnosis of cancer in the future.

Indexed as

ANNbreast cancerPPISVMWGCNA

Identifiers

PMID34079578
PMCPMC8165442

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.